Literature DB >> 9502415

Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states.

A Pagenstecher1, A K Stalder, C L Kincaid, S D Shapiro, I L Campbell.   

Abstract

Matrix metalloproteinases (MMPs) are implicated in the pathogenesis of inflammatory disorders of the central nervous system (CNS) whereas the contribution of the major endogenous counter-regulators of MMPs, the tissue inhibitors of the matrix metalloproteinases (TIMPs), is unclear. We investigated the temporal and spatial expression patterns in the CNS of nine MMP genes and three TIMP genes in normal mice, in mice with EAE, and in transgenic mice with astrocyte (glial fibrillary acidic protein)-targeted expression of the cytokines interleukin-3 (macrophage/microglial demyelinating disease), interleukin-6 (neurodegenerative disease), or tumor necrosis factor-alpha (lymphocytic encephalomyelitis). In normal mice, the MMPs MT1-MMP, stromelysin 3, and gelatinase B were expressed at low levels, whereas high expression of TIMP-2 and TIMP-3 was observed predominantly in neurons and in the choroid plexus, respectively. In EAE and the transgenic mice, significant induction or up-regulation of various MMP genes was observed, the pattern of which was somewhat specific for each of the models, and there was significant induction of TIMP-1. In situ localization experiments revealed a dichotomy between MMP expression that was restricted to leukocytes and possibly microglia within inflammatory lesions and TIMP-1 expression that was observed in activated astrocytes circumscribing the lesions. These findings demonstrate specific spatial and temporal regulation in the expression of individual MMP and TIMP genes in the CNS in normal and inflammatory states. The distinct localization of TIMP-1 and MMP expression during CNS inflammation suggests a dynamic state in which the interplay between these gene products may determine both the size and resolution of the destructive inflammatory focus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9502415      PMCID: PMC1858390     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  62 in total

1.  TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin.

Authors:  J A Nemeth; A Rafe; M Steiner; C L Goolsby
Journal:  Exp Cell Res       Date:  1996-04-10       Impact factor: 3.905

2.  Localization of proteinase expression in the developing rabbit brain.

Authors:  M R Del Bigio; C M Jacque
Journal:  Brain Res Dev Brain Res       Date:  1995-05-26

3.  Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions.

Authors:  A Maeda; R A Sobel
Journal:  J Neuropathol Exp Neurol       Date:  1996-03       Impact factor: 3.685

4.  Structural organization and chromosomal localization of the mouse collagenase type I gene.

Authors:  M Schorpp; M G Mattei; I Herr; S Gack; J Schaper; P Angel
Journal:  Biochem J       Date:  1995-05-15       Impact factor: 3.857

5.  Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790.

Authors:  A K Hewson; T Smith; J P Leonard; M L Cuzner
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

6.  The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis.

Authors:  N Sommer; P A Löschmann; G H Northoff; M Weller; A Steinbrecher; J P Steinbach; R Lichtenfels; R Meyermann; A Riethmüller; A Fontana
Journal:  Nat Med       Date:  1995-03       Impact factor: 53.440

7.  White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues.

Authors:  T Yamada; Y Yoshiyama; H Sato; M Seiki; A Shinagawa; M Takahashi
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

8.  Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2).

Authors:  R Fridman; M Toth; D Peña; S Mobashery
Journal:  Cancer Res       Date:  1995-06-15       Impact factor: 12.701

9.  Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice.

Authors:  C S Chiang; H C Powell; L H Gold; A Samimi; I L Campbell
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808

10.  MMP-9 (gelatinase B) mRNA is expressed during mouse neurogenesis and may be associated with vascularization.

Authors:  R Cañete Soler; Y H Gui; K K Linask; R J Muschel
Journal:  Brain Res Dev Brain Res       Date:  1995-08-28
View more
  74 in total

1.  Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum.

Authors:  C Vaillant; M Didier-Bazès; A Hutter; M F Belin; N Thomasset
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

2.  Intact aggrecan and fragments generated by both aggrecanse and metalloproteinase-like activities are present in the developing and adult rat spinal cord and their relative abundance is altered by injury.

Authors:  M L Lemons; J D Sandy; D K Anderson; D R Howland
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

3.  Characterization of an in vitro rhesus macaque blood-brain barrier.

Authors:  Andrew G MacLean; Marlene S Orandle; John MacKey; Kenneth C Williams; Xavier Alvarez; Andrew A Lackner
Journal:  J Neuroimmunol       Date:  2002-10       Impact factor: 3.478

4.  Matrix metalloproteinase expression correlates with virulence following neurotropic mouse hepatitis virus infection.

Authors:  Jiehao Zhou; Stephen A Stohlman; Roscoe Atkinson; David R Hinton; Norman W Marten
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

5.  Production and Roles of Glial Tissue Inhibitor of Metalloproteinases-1 in Human Immunodeficiency Virus-1-Associated Dementia Neuroinflammation: A Review.

Authors:  C Chao; A Ghorpade
Journal:  Am J Infect Dis       Date:  2009

6.  Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis.

Authors:  S L Leib; D Leppert; J Clements; M G Täuber
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

7.  Persisting vasculitis after pneumococcal meningitis.

Authors:  Deborah Pugin; Jean-Christophe Copin; Marie-Christelle Goodyear; Theodor Landis; Yvan Gasche
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

8.  Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice.

Authors:  Stephen J Crocker; Jason K Whitmire; Ricardo F Frausto; Parntip Chertboonmuang; Paul D Soloway; J Lindsay Whitton; Iain L Campbell
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

9.  CCAAT/enhancer binding protein β expression is increased in the brain during HIV-1-infection and contributes to regulation of astrocyte tissue inhibitor of metalloproteinase-1.

Authors:  Jerel Fields; Jessica Gardner-Mercer; Kathleen Borgmann; Ian Clark; Anuja Ghorpade
Journal:  J Neurochem       Date:  2011-03-14       Impact factor: 5.372

10.  Immunohistochemical analysis of TIMP-2 and collagen types I and IV in experimental spinal cord ischemia-reperfusion injury in rats.

Authors:  Ihsan Anik; Sibel Kokturk; Hamza Genc; Burak Cabuk; Kenan Koc; Sadan Yavuz; Sureyya Ceylan; Savas Ceylan; Levent Kamaci; Yonca Anik
Journal:  J Spinal Cord Med       Date:  2011       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.